The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Alnylam Pharmaceuticals Inc shares valued at $3,124,217 were sold by BONNEY MICHAEL W on May 15 ’25. At $277.71 per share, BONNEY MICHAEL W sold 11,250 shares. The insider’s holdings dropped to 16,804 shares worth approximately $4.86 million following the completion of this transaction.
Also, BONNEY MICHAEL W purchased 11,250 shares, netting a total of over 3,032,212 in proceeds.
Before that, Reitan Colleen F had added 32 shares to its account. In a trade valued at $9,152, the Director bought Alnylam Pharmaceuticals Inc shares for $286.00 each. Upon closing the transaction, the insider’s holdings increased to 32 shares, worth approximately $9248.0.
As published in their initiating research note from Redburn Atlantic on March 31, 2025, Alnylam Pharmaceuticals Inc [ALNY] has been a Buy and the price target has been revised to $353. Analysts at JP Morgan upgraded the stock from ‘”a Neutral”‘ to ‘”an Overweight”‘ outlook in a report released in late March. As of November 12, 2024, Wolfe Research has decreased its “Peer perform” rating to a “an Underperform” for ALNY. Earlier on October 16, 2024, Scotiabank initiated its rating. Their recommendation was “a Sector outperform” for ALNY stock.
Analyzing ALNY Stock Performance
During the last five days, there has been a surge of approximately 1.98%. Over the course of the year, Alnylam Pharmaceuticals Inc shares have jumped approximately 22.82%. Shares of the company reached a 52-week high of $300.90 on 03/24/25 and a 52-week low of $205.87 on 04/09/25.
Support And Resistance Levels for Alnylam Pharmaceuticals Inc (ALNY)
According to the 24-hour chart, there is a support level at 285.10, which, if violated, would cause prices to drop to 281.21. In the upper region, resistance lies at 292.22. The next price resistance is at 295.44. RSI (Relative Strength Index) is 62.52 on the 14-day chart, showing neutral technical sentiment.
